wherein R^2 is

(a) a Ci-6 alkyl group (e.g., methyl, ethyl, propyl, butyl, isobutyl, isopentyl) ;

(b) a Ci-6 alkoxy group (e.g., methoxy, tert-butoxy) ;

(c) an amino group optionally mono- or di-substituted by Ci_{-6} alkyl group(s) (e.g., methyl, ethyl, propyl, isopropyl) ;

or the like; or

(2) a 5-membered aromatic heterocyclic group (e.g., pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, preferably isoxazolyl) optionally substituted by 1 to 3 substituents selected from a $Ci-_6$ alkyl group;

R^3 is a Ci-6 alkyl group optionally substituted by 1 to 3 halogen atoms (e.g., a fluorine atom);


R^4 is a hydrogen atom;

X is 0 or CH_2;

ring A is a 4- to 6-membered nitrogen-containing non-aromatic heterocycle (the heterocycle is optionally crosslinked) or ~~cyclhexane~~cyclohexane;

ring P and ring Q are condensed to form

[0143]




or

[0144]

CLAIMS

1. A compound represented by the formula (I)



(I)

wherein

R^1 is

(1) a group represented by the formula: $-COR^2$

wherein R^2 is

(a) a C_{1-6} alkyl group;

(b) a C_{1-6} alkoxy group; or

(c) an amino group optionally mono- or di-substituted by C_{1-6} alkyl group(s); or

(2) a 5-membered aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from a C_{1-6} alkyl group;


R^3 is a C_{1-6} alkyl group optionally substituted by 1 to 3 halogen atoms;

R^4 is a hydrogen atom;


X is O or CH_2;

ring A is a 4- to 6-membered nitrogen-containing non-aromatic heterocycle (the heterocycle is optionally crosslinked) or cyclohexane;


ring P and ring Q are condensed to form









,



,



,


,

,

,

,

or

,

in each of which ring Q is optionally substituted by 1 to 3 halogen atoms; and

R^6 is a C_{1-6} alkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a C_{3-6} cycloalkyl group,

~~R^1 is a group represented by the formula: $-COR^2$ wherein R^2 is a hydrogen atom or a substituent, an optionally substituted 5- or 6-membered aromatic heterocyclic group or an optionally substituted phenyl group;~~

~~R^3 is a C_{1-6} alkyl group optionally substituted by halogen atom(s), or an optionally substituted C_{3-6} cycloalkyl group;~~

~~R^4 is a hydrogen atom or a substituent;~~

~~X is O, CO, $CR^{5a}R^{5b}$ wherein R^{5a} and R^{5b} are each independently a hydrogen atom, a halogen atom or an optionally substituted C_{1-6} alkyl group, NR^{5c} wherein R^{5c} is a hydrogen atom or an optionally substituted C_{1-6} alkyl group, S, SO or $S(O)_2$;~~

~~ring A is an optionally further substituted 4- to 7-membered non-aromatic ring (the ring is optionally crosslinked);~~

~~ring P is a 5-membered aromatic heterocycle, and~~


~~ring Q is an optionally further substituted 6-membered ring, and~~

~~ring P and ring Q are condensed to form an optionally further substituted bicyclic aromatic heterocycle; and~~

~~R^5 is an optionally substituted C_{1-6} alkyl group or an optionally substituted C_{3-6} cycloalkyl group,~~

or a salt thereof.

~~2. A compound represented by the formula (I)~~



wherein

R^1 is a group represented by the formula: $-COR^2$ wherein R^2 is a hydrogen atom or a substituent, an optionally substituted 5- or 6-membered aromatic heterocyclic group or an optionally substituted phenyl group;

R^3 is a C_{1-6} alkyl group optionally substituted by halogen atom(s), or an optionally substituted C_{3-6} cycloalkyl group;

R^4 is a hydrogen atom or a substituent;

X is O, CO, $CR^{5a}R^{5b}$ wherein R^{5a} and R^{5b} are each independently a hydrogen atom, a halogen atom or an optionally substituted C_{1-6} alkyl group, NR^{5c} wherein R^{5c} is a hydrogen atom or an optionally substituted C_{1-6} alkyl group, S, SO or $S(O)_2$;

ring A is an optionally further substituted 4- to 7-membered non-aromatic ring (the ring is optionally crosslinked);

ring P is a 5-membered aromatic heterocycle, and

ring Q is an optionally further substituted 6-membered aromatic ring, and

ring P and ring Q are condensed to form an optionally further substituted bicyclic aromatic heterocycle; and

R^6 is an optionally substituted C_{1-6} alkyl group or an optionally substituted C_{3-6} cycloalkyl group,

or a salt thereof.

3. The compound or salt of claim 1, wherein R^1 is

(1) a group represented by the formula: $-COR^2$ wherein R^2 is

(a) a C_{1-6} alkyl group;

(b) a C_{1-6} alkoxy group;

(c) an amino group optionally mono- or di-substituted by C_{1-6} alkyl group(s); or

~~(2) a 5-membered aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from a halogen atom and a C_{1-4} alkyl group.~~

~~4. The compound or salt of claim 1, wherein R^5 is a C_{1-6} alkyl group optionally substituted by 1 to 3 halogen atoms, or a C_{3-6} cycloalkyl group optionally substituted by 1 to 5 halogen atoms or 1 to 5 C_{1-3} alkyl groups.~~


~~5. The compound or salt of claim 1, wherein~~
~~R^4 is a hydrogen atom;~~
~~R^6 is a C_{1-6} alkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a C_{3-6} cycloalkyl group; and~~
~~X is O or CH_2.~~


~~6~~2. The compound or salt of claim 1, wherein ring A is azetidine, pyrrolidine, piperidine, piperazine, 8-azabicyclo[3.2.1]octane or cyclohexane.

~~7. The compound or salt of claim 1, wherein ring P is oxazole, thiazole, furan, pyrazole or 1,2,3-triazole.~~

~~8. The compound or salt of claim 1, wherein ring Q is benzene, pyridine or cyclohexa-1,3-diene, each of which is optionally further substituted by 1 to 3 halogen atoms.~~

~~9. The compound or salt of claim 1, wherein ring P and ring Q are condensed to form a fused ring represented by the formula:~~





~~each of which optionally has additional 1 to 3 halogen atoms on the ring Q.~~

~~103~~. N-[(1S)-2-({1-[6-(Cyclopropylmethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl}oxy)-1-methylethyl]acetamide or a salt thereof.

~~114~~. N-[(1S)-2-({1-[5-(Cyclopropylmethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl}oxy)-1-methylethyl]acetamide or a salt thereof.

~~12~~ 5. N-[(1S)-3-{1-[6-(Cyclopropylmethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl}-1-methylpropyl]acetamide or a salt thereof.

~~136~~. N-[(1S)-2-({1-[6-(2-Cyclopropylethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl}oxy)-1-methylethyl]acetamide or a salt thereof.

~~147~~. A medicament comprising the compound or salt of claim 1.

~~158~~. The medicament of claim ~~147~~, which is an acetyl-CoA carboxylase inhibitor.

~~169~~. The medicament of claim ~~147~~, which is an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia or cancer.

~~17. A method for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia or cancer in a mammal, which comprises administering an effective~~

~~amount of the compound or salt of claim 1 to the mammal.~~

~~18~~10. Use of the compound or salt of claim 1, for the production of an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia or cancer.